Skip to main content
Top
Published in: Abdominal Radiology 8/2019

01-08-2019 | Magnetic Resonance Imaging | Kidneys, Ureters, Bladder, Retroperitoneum

Can magnetic resonance imaging differentiate among transurethral bulking agent, urethral diverticulum, and periurethral cyst?

Authors: Thitinan Chulroek, Dearada Wangcharoenrung, Kamonwon Cattapan, Hamed Kordbacheh, Alissa J. Mitchell, Mukesh G. Harisinghani, Elise J. B. De

Published in: Abdominal Radiology | Issue 8/2019

Login to get access

Abstract

Purpose

To evaluate magnetic resonance imaging findings that differentiate among periurethral bulking agents (primarily collagen), urethral diverticulum, and periurethral cyst.

Methods

We searched our radiologic database retrospectively from 2001 to 2017 for periurethral cystic lesions, identifying a total of 50 patients with 68 lesions. Final diagnoses in 68 lesions were bulking agents (27), urethral diverticula (29), and periurethral cysts (12). Two abdominal radiologists, blinded to clinical history, independently evaluated T1, T2, and post-contrast images. The readers assessed number, morphological features, location, connection to urethra and mass effect, signal intensity, and enhancement for each lesion. Fisher exact test and logistic regression analysis were performed for each univariate significant feature. The operative and pathologic reports were the reference standard.

Results

Magnetic resonance imaging features found more often in bulking agents versus urethral diverticulum were multiple lesions (P = 0.011), upper or upper-mid-urethral location (P ≤ 0.0001), lack of internal fluid/fluid level (P = 0.002), no urethral connection (P = 0.005), T1 isointensity, and T2 mild hyperintensity compared to muscles but lower T2 signal than urine (P < 0.0001). Most cases of urethral diverticula and periurethral cysts were detected at mid- and lower urethra. Urethral diverticula were larger than bulking agents and periurethral cysts (P = 0.005 and P = 0.023) (mean diameter = 24, 16, 15 mm, respectively). Most bulking agents (93%) and urethral diverticula (90%) showed mass effect on urethra, while periurethral cysts (75%) did not (P < 0.0001).

Conclusion

Signal intensity and lesion characterization on magnetic resonance imaging can significantly differentiate bulking agent from urethral diverticulum and periurethral cyst. Radiologists should consider differential diagnosis of a bulking agent, especially when distinguishing characteristics described here are present to prevent incorrect diagnosis and ultimately unnecessary surgical intervention.
Literature
16.
go back to reference Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRef Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRef
17.
go back to reference Maki DD, Banner MP, Ramchandani P, et al (2000) Injected periurethral collagen for postprostatectomy urinary incontinence: MR and CT appearance. Abdom Imaging 25:658–662CrossRefPubMed Maki DD, Banner MP, Ramchandani P, et al (2000) Injected periurethral collagen for postprostatectomy urinary incontinence: MR and CT appearance. Abdom Imaging 25:658–662CrossRefPubMed
18.
go back to reference Appell RA (1994) Collagen injection therapy for urinary incontinence. Urol Clin North Am 21:177–182PubMed Appell RA (1994) Collagen injection therapy for urinary incontinence. Urol Clin North Am 21:177–182PubMed
Metadata
Title
Can magnetic resonance imaging differentiate among transurethral bulking agent, urethral diverticulum, and periurethral cyst?
Authors
Thitinan Chulroek
Dearada Wangcharoenrung
Kamonwon Cattapan
Hamed Kordbacheh
Alissa J. Mitchell
Mukesh G. Harisinghani
Elise J. B. De
Publication date
01-08-2019
Publisher
Springer US
Published in
Abdominal Radiology / Issue 8/2019
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-019-02052-w

Other articles of this Issue 8/2019

Abdominal Radiology 8/2019 Go to the issue

Classics in Abdominal Radiology

The “inverted Napoleon’s hat” sign

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.